GSK, ViiV offer sneak peek of PhIII data on in-house two-drug HIV combo, touting non-inferiority
Pressing on with its ambitious goal to outshine Gilead in the HIV space, GlaxoSmithKline is now armed with positive data on its two-drug regimen from a pair of Phase III studies — if we take their word for it.
ViiV Healthcare — GSK’s dedicated HIV arm — reported overnight that GEMINI-1 and GEMINI-2 met their primary endpoint based on plasma HIV-1 RNA <50 copies per millilitre (c/mL) at week 48, essentially showing non-inferiority of dolutegravir and lamivudine compared to the standard three-drug regimen. In addition to safety information, that’s as much as GSK is willing to divulge at the moment, choosing to save the details for an upcoming medical conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.